These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 24687088)

  • 21. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
    Issa GC; Kantarjian HM; Xiao L; Ning J; Alvarado Y; Borthakur G; Daver N; DiNardo CD; Jabbour E; Bose P; Jain N; Kadia TM; Naqvi K; Pemmaraju N; Takahashi K; Verstovsek S; Andreeff M; Kornblau SM; Estrov Z; Ferrajoli A; Garcia-Manero G; Ohanian M; Wierda WG; Ravandi F; Cortes JE
    Leukemia; 2020 Nov; 34(11):2914-2924. PubMed ID: 32546726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
    Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
    J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CPX-351 (vyxeos) in AML.
    Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
    Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
    Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
    Cortes JE; Lin TL; Asubonteng K; Faderl S; Lancet JE; Prebet T
    J Hematol Oncol; 2022 Oct; 15(1):155. PubMed ID: 36289532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
    Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
    Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
    Lemoli RM; Montesinos P; Jain A
    Crit Rev Oncol Hematol; 2023 May; 185():103984. PubMed ID: 37028531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
    Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
    Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
    Burnett AK; Russell NH; Hills RK; Kell J; Cavenagh J; Kjeldsen L; McMullin MF; Cahalin P; Dennis M; Friis L; Thomas IF; Milligan D; Clark RE;
    Blood; 2015 Jun; 125(25):3878-85. PubMed ID: 25833957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
    Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
    Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose daunorubicin in older patients with acute myeloid leukemia.
    Löwenberg B; Ossenkoppele GJ; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Maertens J; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; van Marwijk Kooy M; Verdonck LF; Beck J; Döhner H; Gratwohl A; Pabst T; Verhoef G; ; ;
    N Engl J Med; 2009 Sep; 361(13):1235-48. PubMed ID: 19776405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
    Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
    Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
    J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
    Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
    Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
    Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.